“The purpose of this study was to determine the prevalence of hepatitis C virus (HCV), patient characteristics, and receipt of appropriate care in a sample of patients treated with buprenorphine for their opioid use disorders in a primary care setting. Nearly half of patients (47.7%) receiving office–based treatment with buprenorphine for their opioid use disorder had a positive Hepatitis C Virus antibody screening test although initiation of HCV treatment was nearly non–existent (2.21%).
The sample comprised 700 patients.
Slightly less than half of all patients (n= 334, 47.7%) were HCV Ab positive, and were significantly more likely to be older, Hispanic or African American, have diagnoses of post-traumatic stress disorder (PTSD) or bipolar disorder, have prior heroin or cocaine use, and be HIV-infected.
Among the 334 HCV Ab positive patients, 226 (67.7%) had detectable HCV ribonucleic acid (RNA) indicating chronic HCV infection; only 5 patients (2.21%) with chronic HCV infection ever initiated treatment.”
Source: MDLinx.com – February 19, 2016